Backyard gene editing risks creating a monster
By Editorial,
New Scientist
| 03. 15. 2017
The gene-editing revolution continues to gather pace, but it is also throwing us curveballs. One is an unexpected technical hitch (see “Mosaic problem stands in the way of gene editing embryos“). Another concerns oversight and ownership: who gets to use it, and for what?
In January, David Ishee, a dog breeder from Mississippi, told the US Food and Drug Administration that he planned to use CRISPR gene editing to fix a mutation that makes Dalmatians prone to kidney disease (see “How dogs are helping decode the genetic roots of personality“).
The FDA responded by telling Ishee that he could experiment, but not sell or even give away his modified dogs. The law was recently amended so that gene-edited animals require approval before they can be sold.
But the FDA also said it would reconsider if presented with evidence that certain types of gene editing pose “minimal risk”. How that will be defined or decided is not clear, but it means we could soon see a cottage industry of gene-edited animals created in biohackers’ sheds.
At first glance...
Related Articles
By Ewen Callaway, Nature | 08.04.2025
For months, researchers in a laboratory in Dallas, Texas, worked in secrecy, culturing grey-wolf blood cells and altering the DNA within. The scientists then plucked nuclei from these gene-edited cells and injected them into egg cells from a domestic dog ...
Mike Pennington / Dolly the sheep, National
Museums of Scotland, Edinburgh / CC BY-SA 2.0
The first mammal cloned from an adult cell, Dolly the sheep, was born on July 5, 1996. She became a global star, but neither she nor British embryologist Ian Wilmut (her foster daddy) got rich, though Wilmut did eventually receive a knighthood for leading the successful team. Dolly lived a pampered life and died in 2003; her body remains on display at the National Museum...
By David Coltman, Carson Mitchell, Liam Alastair Wayde Carter, and Tommy Galfano, The Conversation | 05.12.2025
Gray wolf by Jessica Eirich via Unsplash
“I’m not a scarcity guy, I’m an abundance guy”
– Colossal co-founder and CEO Ben Lamm, The New Yorker, 4/14/25
Even the most casual consumers of news will have seen the run of recent headlines featuring the company Colossal Biosciences. On March 4, they announced with great fanfare the world’s first-ever woolly mice, as a first step toward creating a woolly mammoth. Then they topped that on April 7 by unveiling one...